References
- Hayward WS, Neel BG, Astrin SM. Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis. Nature. 1981;290:475–480.
- Amati B, Brooks MW, Levy N, et al. Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell. 1993;72:233–245.
- Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008;8:976–990.
- Cai Q, Medeiros LJ, Xu X, et al. MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management. Oncotarget. 2015;6:38591–38616.
- Li S, Weiss VL, Wang XJ, et al. High-grade B-cell lymphoma with MYC rearrangement and without BCL2 and BCL6 rearrangements is associated with high p53 expression and a poor prognosis. Am J Surg Pathol. 2016;40:253–261.
- Taub R, Kirsch I, Morton C, et al. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci USA. 1982;79:7837–7841.
- Chiecchio L, Dagrada GP, Protheroe RK, et al. Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case. Haematologica. 2009;94:1024–1028.
- Chiecchio L, Dagrada GP, White HE, et al. Frequent upregulation of MYC in plasma cell leukemia. Genes Chromosomes Cancer. 2009;48:624–636.
- Glitza IC, Lu G, Shah R, et al. Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma. Leuk Lymphoma. 2015;56:602–607.
- Wu SP, Pfeiffer RM, Ahn I, et al. Impact of genes highly correlated with MMSET myeloma on survival of non-MMSET myeloma patients. Clin Cancer Res. 2016. [Epub ahead of print]. doi: 10.1158/1078-0432.CCR-15-2366.
- Szabo AG, Gang AO, Pedersen MØ, et al. Overexpression of c-myc is associated with adverse clinical features and worse overall survival in multiple myeloma. Leuk Lymphoma. 2016;57:2526–2534.